Yicura BioMed completes first closing of Series B financing

Detailed summary
Clinical-stage immunotherapy firm Yicura BioMed completed the first closing of its Series B funding round led by Gobi Partners on 13 November 2026 to advance its ICVAX HIV product.
HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong. Their participation reflects shared confidence in Yicura's clinical development path.
The issuer is solely responsible for the content of this announcement.
Opening of the article, excerpted from Vietnam Investment Review. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (vir.com.vn)



